MTNB | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 3%

Liquidity 50%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

12.39%

1 Month

1.15%

3 Months

-17.97%

6 Months

-61.44%

1 Year

3.70%

2 Year

239.38%

Key data

Stock price

$0.62

P/E Ratio

0.00

DAY RANGE

$0.57 - $0.63

EPS

-$1.79

52 WEEK RANGE

$0.48 - $3.09

52 WEEK CHANGE

-$7.91

MARKET CAP

9.614 M

YIELD

N/A

SHARES OUTSTANDING

6.406 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

2.72

PUBLIC FLOAT

AVERAGE 10 VOLUME

$52,056

AVERAGE 30 VOLUME

$34,420

Company detail

CEO: Jerome D. Jabbour
Region: US
Website: matinasbiopharma.com
Employees: 30
IPO year: 2017

Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Matinas BioPharma Holdings, Inc. focuses on the discovery and development of various product candidates. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients.

MTNB - Matinas BioPharma Holdings, Inc.